Q-omics provides the consensus-scored GGA3 profile across patient tissues and cancer cell-line models. GGA3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GGA3 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, GGA3 protein abundance shows 22,496 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRP, and GBM as cancer lineages where GGA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GGA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GGA3 survival associations across molecular data types. GGA3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GGA3 RNA expression–survival associations across cancer types. High GGA3 expression shows unfavorable associations in LIHC, KIRC and KICH, but favorable associations in BRCA, MESO and HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GGA3 RNA expression.
This table summarizes GGA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GGA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GGA3 shows lower tumor expression in KICH and higher tumor expression in KIRP, LIHC, COAD, CHOL and STAD. The KIRP box plot shows higher GGA3 RNA expression in tumor versus normal tissue (log2 FC = +1.065, t-test p < 0.001).
This table shows molecular features associated with GGA3 in patient tissues and cancer cell lines. In patient samples, GGA3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GGA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
